Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 Dugie Standeford For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say. Continue reading -> The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Global Health Funding Flows As WHO, Gavi, Global Fund Benefit 27/03/2018 William New Actions by governments in recent days show funding for global health continues to be a priority for some countries. Geneva-based institutions and their programs around the world are among the beneficiaries. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities 08/02/2018 Catherine Saez World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job. Continue reading -> Posts navigation Older postsNewer posts
The Patent Paradox In Brazil And Its Implications For Access To Medicines 18/05/2018 Guest contributor Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading -> Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Global Health Funding Flows As WHO, Gavi, Global Fund Benefit 27/03/2018 William New Actions by governments in recent days show funding for global health continues to be a priority for some countries. Geneva-based institutions and their programs around the world are among the beneficiaries. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities 08/02/2018 Catherine Saez World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job. Continue reading -> Posts navigation Older postsNewer posts
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 Catherine Saez Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need. Continue reading -> Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Global Health Funding Flows As WHO, Gavi, Global Fund Benefit 27/03/2018 William New Actions by governments in recent days show funding for global health continues to be a priority for some countries. Geneva-based institutions and their programs around the world are among the beneficiaries. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities 08/02/2018 Catherine Saez World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job. Continue reading -> Posts navigation Older postsNewer posts
Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 Catherine Saez The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled. Continue reading -> Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Global Health Funding Flows As WHO, Gavi, Global Fund Benefit 27/03/2018 William New Actions by governments in recent days show funding for global health continues to be a priority for some countries. Geneva-based institutions and their programs around the world are among the beneficiaries. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities 08/02/2018 Catherine Saez World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job. Continue reading -> Posts navigation Older postsNewer posts
Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 William New BANGKOK - Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said. Continue reading -> Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Global Health Funding Flows As WHO, Gavi, Global Fund Benefit 27/03/2018 William New Actions by governments in recent days show funding for global health continues to be a priority for some countries. Geneva-based institutions and their programs around the world are among the beneficiaries. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities 08/02/2018 Catherine Saez World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job. Continue reading -> Posts navigation Older postsNewer posts
Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 Guest contributor Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading -> Global Health Funding Flows As WHO, Gavi, Global Fund Benefit 27/03/2018 William New Actions by governments in recent days show funding for global health continues to be a priority for some countries. Geneva-based institutions and their programs around the world are among the beneficiaries. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities 08/02/2018 Catherine Saez World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job. Continue reading -> Posts navigation Older postsNewer posts
Global Health Funding Flows As WHO, Gavi, Global Fund Benefit 27/03/2018 William New Actions by governments in recent days show funding for global health continues to be a priority for some countries. Geneva-based institutions and their programs around the world are among the beneficiaries. Continue reading -> WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities 08/02/2018 Catherine Saez World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job. Continue reading -> Posts navigation Older postsNewer posts
WHO: Access To Hepatitis C Treatment Increasing, But Most Patients Undiagnosed 13/03/2018 Catherine Saez Access to hepatitis C treatments is increasing, so are therapeutic options, but most of those living with the disease are not diagnosed and thus remain untreated, the World Health Organization found in a new report. Upper-middle income and high-income countries continue to pay high prices, impeding equitable access, and those countries which have been most successful in increasing access have mobilised a strong government response, the report found. Continue reading -> Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities 08/02/2018 Catherine Saez World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job. Continue reading -> Posts navigation Older postsNewer posts
Study: TRIPS Flexibilities Widely Used By Countries, Contrary To Reports 02/03/2018 Catherine Saez Despite the widespread view that the flexibilities included in international trade rules are not often used, a new study found that countries make extensive use of those flexibilities. Continue reading -> WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities 08/02/2018 Catherine Saez World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job. Continue reading -> Posts navigation Older postsNewer posts
WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities 08/02/2018 Catherine Saez World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job. Continue reading -> Posts navigation Older postsNewer posts